Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Myelofibrosis
NCT05467800Phase 2Active, not recruiting
- Sponsor
- John Mascarenhas
- Start
- Aug 2022
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in myelofibrosis (MF), sponsored by John Mascarenhas. Started Aug 2022; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05467800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467800.